Jon Burrows
University of Chicago
21 Papers
43 Citations
Jon Burrows is an academic researcher from University of Chicago. The author has contributed to research in topics: Cancer & Biology. The author has an hindex of 8, co-authored 21 publications.
Chat about Author
Papers
High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy
Paolo Nuciforo,Sheeno Thyparambil,Claudia Aura,Ana C. Garrido-Castro,Marta Vilaro,Vicente Peg,Jose Jimenez,Rocio Vicario,Fabiola Cecchi,William Hoos,Jon Burrows,Todd Hembrough,Juan Carles Ferreres,Jose Perez-Garcia,Joaquín Arribas,Javier Cortes,Maurizio Scaltriti +16 more
TL;DR: Quantitative measurement of HER2 may more accurately identify breast cancer patients who will respond to anti‐HER2 treatments and be able to predict benefit from anti-HER2 therapy.
83
Selected Reaction Monitoring (SRM) Analysis of Epidermal Growth Factor Receptor (EGFR) in Formalin Fixed Tumor Tissue
Todd Hembrough,Sheeno Thyparambil,Wei-Li Liao,Marlene Darfler,Joseph Abdo,Kathleen Bengali,Paul J. Taylor,Jiefei Tong,Humberto Lara-Guerra,Thomas K. Waddell,Michael F. Moran,Ming-Sound Tsao,Ming-Sound Tsao,David B. Krizman,Jon Burrows +14 more
TL;DR: This assay can be used as part of a complementary or companion diagnostic strategy to support novel therapies currently under development and demonstrates the potential to identify candidates for EGFR-inhibitor therapy, predict treatment outcome, and reveal mechanisms of therapeutic resistance.
Application of Selected Reaction Monitoring for Multiplex Quantification of Clinically Validated Biomarkers in Formalin-Fixed, Paraffin-Embedded Tumor Tissue
Todd Hembrough,Sheeno Thyparambil,Wei-Li Liao,Marlene Darfler,Joseph Abdo,Kathleen Bengali,Stephen M. Hewitt,Richard A. Bender,David B. Krizman,Jon Burrows +9 more
TL;DR: The development of a quantitative, multiplexed, mass spectrometry-based selected reaction monitoring (SRM) assay for four therapeutically important targets: epidermal growth factor receptor, human EGF receptor (HER)-2, HER3, and insulin-like growth factor-1 receptor is described.
70
Absolute Quantitation of Met Using Mass Spectrometry for Clinical Application: Assay Precision, Stability, and Correlation with MET Gene Amplification in FFPE Tumor Tissue
Daniel V.T. Catenacci,Wei-Li Liao,Sheeno Thyparambil,Les Henderson,Peng Xu,Lei Zhao,Brittany Rambo,John Hart,Shu-Yuan Xiao,Kathleen Bengali,Jamar Uzzell,Marlene Darfler,David B. Krizman,Fabiola Cecchi,Donald P. Bottaro,Theodore Karrison,Timothy D. Veenstra,Todd Hembrough,Jon Burrows +18 more
TL;DR: The Met SRM assay measured the absolute Met levels in clinical tissues with high precision and provided a quantitative and linear measurement of Met expression, reliably distinguishing between non-amplified and amplified MET tumors.
Mass spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: Comparison to IHC and FISH
Daniel V.T. Catenacci,Wei-Li Liao,Lei Zhao,Emma Whitcomb,Les Henderson,Peng Xu,Emily O'Day,Sheeno Thyparambil,Kathleen Bengali,Jamar Uzzell,Marlene Darfler,Fabiola Cecchi,Adele Blackler,David Krisman,Yung-Jue Bang,John Hart,Shu-Yuan Xiao,Sang Mee Lee,Jon Burrows,Todd Hembrough +19 more
TL;DR: Compared to IHC, SRM-MS provided more objective and quantitative Her2 expression with excellent HER2/CEP17 FISH correlation and fewer ‘equivocal’ cases, and demonstrated a refined HER2 expression assay for clinical application.